Drug negotiation provisions are so far absent from the current working version of the build back better legislation, a reflection of the power of pharma industry lobbying. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
